BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21187458)

  • 1. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
    Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
    Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
    Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.
    Yamauchi K; Sakurai H; Kimura T; Wiriyasermkul P; Nagamori S; Kanai Y; Kohno N
    Cancer Lett; 2009 Apr; 276(1):95-101. PubMed ID: 19058911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases).
    Takeuchi K; Ogata S; Nakanishi K; Ozeki Y; Hiroi S; Tominaga S; Aida S; Matsuo H; Sakata T; Kawai T
    Lung Cancer; 2010 Apr; 68(1):58-65. PubMed ID: 19559497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
    Kobayashi K; Ohnishi A; Promsuk J; Shimizu S; Kanai Y; Shiokawa Y; Nagane M
    Neurosurgery; 2008 Feb; 62(2):493-503; discussion 503-4. PubMed ID: 18382329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
    Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression and functional characterization of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells.
    Kim SG; Kim HH; Kim HK; Kim CH; Chun HS; Kanai Y; Endou H; Kim DK
    Anticancer Res; 2006; 26(3A):1989-96. PubMed ID: 16827134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration.
    Janpipatkul K; Suksen K; Borwornpinyo S; Jearawiriyapaisarn N; Hongeng S; Piyachaturawat P; Chairoungdua A
    Cell Signal; 2014 Aug; 26(8):1668-79. PubMed ID: 24726839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.
    Furuya M; Horiguchi J; Nakajima H; Kanai Y; Oyama T
    Cancer Sci; 2012 Feb; 103(2):382-9. PubMed ID: 22077314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
    Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
    Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
    Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
    Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
    Cheng H; An SJ; Zhang XC; Dong S; Zhang YF; Chen ZH; Chen HJ; Guo AL; Lin QX; Wu YL
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):637-46. PubMed ID: 20495920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; BarĂ³n A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Nakajima T; Mori M
    Lung Cancer; 2009 Oct; 66(1):120-6. PubMed ID: 19171406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: role in cell growth.
    Liu XM; Reyna SV; Ensenat D; Peyton KJ; Wang H; Schafer AI; Durante W
    FASEB J; 2004 Apr; 18(6):768-70. PubMed ID: 14977877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. System L-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells.
    Kim DK; Kim IJ; Hwang S; Kook JH; Lee MC; Shin BA; Bae CS; Yoon JH; Ahn SG; Kim SA; Kanai Y; Endou H; Kim JK
    Neurosci Res; 2004 Dec; 50(4):437-46. PubMed ID: 15567481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.